<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39390502</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1752-1947</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>Journal of medical case reports</Title><ISOAbbreviation>J Med Case Rep</ISOAbbreviation></Journal><ArticleTitle>Coronavirus-disease-2019-associated Stevens-Johnsons syndrome in a 15-year-old boy: a case report and review of the literature.</ArticleTitle><Pagination><StartPage>493</StartPage><MedlinePgn>493</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">493</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13256-024-04842-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Stevens-Johnson syndrome (SJS) is a life-threatening condition characterized by high fever and severe mucocutaneous lesions, often triggered by drugs or infection. During the coronavirus disease 2019 pandemic, there was a marked increase in Stevens-Johnson syndrome cases, but relatively few cases were reported in children. The present article reports a pediatric case of Stevens-Johnson syndrome due to coronavirus disease 2019 infection and provides a review of the most relevant literature.</AbstractText><AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">A previously healthy 15-year-old Han Chinese boy from China presented to the hospital with oral ulcers, conjunctival hyperemia, and widespread maculopapular rash. He had a history of fever 9 days prior and tested positive for coronavirus disease 2019 infection. Upon admission, his rash and mucosal lesions worsened, with the development of blisters on the fingertips of both hands, ocular pain, photophobia, and erosive lesions on the genital mucosa with exudation. He was diagnosed with Stevens-Johnson syndrome and received treatment with methylprednisolone, intravenous immunoglobulin, and dermatological and mucosal care. The patient's condition was managed, and the dosage of high-dose intravenous methylprednisolone was tapered down, followed by a transition to oral prednisolone. He was discharged without sequelae.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We should be aware that coronavirus disease 2019 infection is associated with the development of Stevens-Johnson syndrome in children and may lead to a wide spectrum of dermatologic presentations. Although Stevens-Johnson syndrome is a relatively rare condition, given its potentially serious consequences, it is crucial to identify it as early as possible and to take appropriate preventive and therapeutic measures to reduce complications and improve the quality of life for patients.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Na</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, Children's Hospital Affiliated to Shandong University (Jinan Children's Hospital), No. 23976 Jingshi Road, Jinan, 250022, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, Children's Hospital Affiliated to Shandong University (Jinan Children's Hospital), No. 23976 Jingshi Road, Jinan, 250022, China. hpylijian@hotmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Med Case Rep</MedlineTA><NlmUniqueID>101293382</NlmUniqueID><ISSNLinking>1752-1947</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>X4W7ZR7023</RegistryNumber><NameOfSubstance UI="D008775">Methylprednisolone</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance></Chemical><Chemical><RegistryNumber>9PHQ9Y1OLM</RegistryNumber><NameOfSubstance UI="D011239">Prednisolone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013262" MajorTopicYN="Y">Stevens-Johnson Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008775" MajorTopicYN="N">Methylprednisolone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016756" MajorTopicYN="N">Immunoglobulins, Intravenous</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011239" MajorTopicYN="N">Prednisolone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Pediatric</Keyword><Keyword MajorTopicYN="N">Stevens–Johnson syndrome</Keyword><Keyword MajorTopicYN="N">Toxic epidermal necrolysis</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>0</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>23</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39390502</ArticleId><ArticleId IdType="pmc">PMC11468181</ArticleId><ArticleId IdType="doi">10.1186/s13256-024-04842-3</ArticleId><ArticleId IdType="pii">10.1186/s13256-024-04842-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Liotti L, Caimmi S, Bottau P, et al. Clinical features, outcomes and treatment in children with drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Acta Biomed. 2019;90(3):52–60. 10.23750/abm.v90i3-S.8165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6502171</ArticleId><ArticleId IdType="pubmed">30830062</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Varghese S, Bassir F, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review of PubMed/MEDLINE case reports from 1980 to 2020. Front Med (Lausanne). 2022;24(9): 949520. 10.3389/fmed.2022.949520.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9449801</ArticleId><ArticleId IdType="pubmed">36091694</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">8420497</ArticleId></ArticleIdList></Reference><Reference><Citation>DeBiasi RL, Song X, Delaney M, et al. Severe coronavirus disease-2019 in children and young adults in the Washington, DC, metropolitan region. J Pediatr. 2020;223:199-203.e1. 10.1016/j.jpeds.2020.05.007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7217783</ArticleId><ArticleId IdType="pubmed">32405091</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuhara J, Kuno T, Takagi H, et al. Clinical characteristics of COVID-19 in children: a systematic review. Pediatr Pulmonol. 2020;55(10):2565–75. 10.1002/ppul.24991.</Citation><ArticleIdList><ArticleId IdType="pubmed">32725955</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou H, Daveluy S. Toxic epidermal necrolysis and Stevens-Johnson syndrome after COVID-19 infection and vaccination. Australas J Dermatol. 2023;64(1):e1–10. 10.1111/ajd.13958.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9878214</ArticleId><ArticleId IdType="pubmed">36484649</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorrell J, Anthony L, Rademaker A, et al. Score of toxic epidermal necrosis predicts the outcomes of pediatric epidermal necrolysis. Pediatr Dermatol. 2017;34(4):433–7. 10.1111/pde.13172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28508417</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol. 2013;69:187.</Citation><ArticleIdList><ArticleId IdType="pubmed">23866879</ArticleId></ArticleIdList></Reference><Reference><Citation>Jouhar L, Yahya M, Elsiddiq S. Toxic epidermal necrolysis associated with COVID-19 infection: a case report. Clin Case Rep. 2022;10: e05565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8918465</ArticleId><ArticleId IdType="pubmed">35310321</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrandiz-Pulido C, Garcia-Patos V. A review of causes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Arch Dis Child. 2013;98:998–1003.</Citation><ArticleIdList><ArticleId IdType="pubmed">23873883</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi CM, Beretta FN, Traverso G, et al. A case report of toxic epidermal necrolysis (TEN) in a patient with COVID-19 treated with hydroxychloroquine: are these two partners in crime? Clin Mol Allergy. 2020;18:19. 10.1186/s12948-020-00133-6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7537980</ArticleId><ArticleId IdType="pubmed">33033459</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang HC, Wang TJ, Lin MH, et al. A review of the systemic treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis. Biomedicines. 2022;10(9):2105. 10.3390/biomedicines10092105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9495335</ArticleId><ArticleId IdType="pubmed">36140207</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35:495–516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2117903</ArticleId><ArticleId IdType="pubmed">17562483</ArticleId></ArticleIdList></Reference><Reference><Citation>Stur K, Karlhofer FM, Stingl G. Soluble FAS ligand: a discriminating feature between drug-induced skin eruptions and viral exanthemas. J Invest Dermatol. 2007;127(4):802–7. 10.1038/sj.jid.5700648.</Citation><ArticleIdList><ArticleId IdType="pubmed">17139262</ArticleId></ArticleIdList></Reference><Reference><Citation>Su SC, Chung WH. Cytotoxic proteins and therapeutic targets in severe cutaneous adverse reactions. Toxins (Basel). 2014;6(1):194–210. 10.3390/toxins6010194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3920257</ArticleId><ArticleId IdType="pubmed">24394640</ArticleId></ArticleIdList></Reference><Reference><Citation>Saeed HN, Chodosh J. Immunologic mediators in Stevens-Johnson syndrome and toxic epidermal necrolysis. Semin Ophthalmol. 2016;31(1–2):85–90. 10.3109/08820538.2015.1115255.</Citation><ArticleIdList><ArticleId IdType="pubmed">26959133</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14(12):1343–50. 10.1038/nm.1884.</Citation><ArticleIdList><ArticleId IdType="pubmed">19029983</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanley EA, Zhang L, O’Hara J, et al. The seven-fold rise in incidence of Stevens-Johnson syndrome &amp; toxic epidermal necrolysis: associations with COVID-19 and the vaccine. Burns. 2024;50(1):87–92. 10.1016/j.burns.2023.06.016.</Citation><ArticleIdList><ArticleId IdType="pubmed">37730480</ArticleId></ArticleIdList></Reference><Reference><Citation>Varol F, Can YY, Sahin E, et al. The role of treatment with plasma exchange therapy in two pediatric toxic epidermal necrolysis cases related to COVID-19. J Clin Apher. 2022;37:516–21. 10.1002/jca.21997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9350357</ArticleId><ArticleId IdType="pubmed">35792366</ArticleId></ArticleIdList></Reference><Reference><Citation>Metbulut AP, Özkaya Parlakay A, Bayhan Gİ, et al. Evaluation of cutaneous symptoms in children infected with COVID-19. Pediatr Allergy Immunol. 2021;32(5):1120–5. 10.1111/pai.13467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8013869</ArticleId><ArticleId IdType="pubmed">33555642</ArticleId></ArticleIdList></Reference><Reference><Citation>Haraguchi S, Tsubokura S, Ozasa K, et al. Pediatric Stevens-Johnson syndrome associated with severe acute respiratory syndrome coronavirus 2 infection. Pediatr Int. 2022;64(1): e15366. 10.1111/ped.15366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9537940</ArticleId><ArticleId IdType="pubmed">36165959</ArticleId></ArticleIdList></Reference><Reference><Citation>Sljivic S, Pogson K, Williams FN, et al. COVID-induced toxic epidermal necrolysis in a 4-year-old female: a case report and literature review. Int J Burns Trauma. 2022;12(5):204–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9677226</ArticleId><ArticleId IdType="pubmed">36420101</ArticleId></ArticleIdList></Reference><Reference><Citation>Parlakay AO, Ozcan S, Karaatmaca B, et al. COVID-19 presenting like Steven Johnson Syndrome in a pediatric patient. Authorea preprints. 2020.</Citation></Reference><Reference><Citation>Aulakh S, Arora R, Sarangal R, et al. Increased predisposition of SJS TEN in COVID-19 patients, presenting as post COVID complication: report of two cases. Indian Dermatol Online J. 2022;13(2):237–9. 10.4103/idoj.idoj_510_21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8917493</ArticleId><ArticleId IdType="pubmed">35287406</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka A, Isei M, Kikuzawa C, et al. Development of toxic epidermal necrolysis in a coronavirus disease 2019 patient with recurrence of positive SARSCoV-2 viral RNA. J Dermatol. 2021;48(3):e144–5. 10.1111/1346-8138.15753.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8014636</ArticleId><ArticleId IdType="pubmed">33439527</ArticleId></ArticleIdList></Reference><Reference><Citation>Emadi S, Hamzelou S, Saffarian Z, et al. Challenges in the treatment of a patient with toxic epidermal necrolysis associated with COVID-19: a case report. Dermatol Ther. 2021;34(1): e14656. 10.1111/dth.14656.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7883031</ArticleId><ArticleId IdType="pubmed">33301196</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulat V, Likic R, Pondeljak N. Pholcodine-induced Stevens-Johnson syndrome in a patient with COVID-19. Postgrad Med J. 2022;98(1161):499–500. 10.1136/postgradmedj-2021-139892.</Citation><ArticleIdList><ArticleId IdType="pubmed">33879549</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa A, Abe R. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis. F1000Res. 2020. 10.12688/f1000research.24748.1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7308994</ArticleId><ArticleId IdType="pubmed">32595945</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>